Skip to main content
. 2021 Jul 16;40(35):5379–5392. doi: 10.1038/s41388-021-01914-2

Fig. 6. ARVib improves enzalutamide treatment in vitro and in vivo.

Fig. 6

A, B CWR22Rv1 cells were treated with DMSO, 20 µM enzalutamide, 0.5 µM ARVibs or their combination. Cell growth was determined at 3 days and colony formation ability was examined by clonogenic assay. C Mice bearing VCaP xenografts were castrated and the relapsed tumors were treated with vehicle control, enzalutamide (25 mg per Kg p.o), ARVib-7 (75 mg per Kg p.o.) or their combination for 24 days (n = 8). Tumor volumes were measured twice weekly. D Tumors were photographed. Scale bar 1 cm. Data represent means ± S.D. from eight mice per group. E Tumors weight. F PSA expression in mice serum was examined. G Kaplan–Meier curves showing survival benefits of ARVib-7 single treatment, ARVib-7 and enzalutamide combination treatment in relapsed VCaP tumors. H Body weight was determined. I IHC staining of Ki67, AR-V7, and HSP70 in each group was performed and quantified. *p < 0.05.